Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Withdrawn phase 2 trial in recurrent ovarian cancer
NL-OMON53922Phase 2Unknown
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2024
- Countries
- 1
01
Overview
Phase 2 trial in ovarian cancer and recurrent ovarian cancer (ROC), sponsored by Regeneron Pharmaceuticals. Status: unknown.
02
Conditions
ovarian cancerrecurrent ovarian cancer (ROC)
Beyond the preview
Go deeper on NL-OMON53922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53922.